Myeloproliferative Neoplasms (MPN)

Akriti Jain, M.D

Institution
Cleveland Clinic
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About

Akriti G Jain, MD treats myeloid disorders at Cleveland Clinic’s Main Campus in Cleveland, Ohio. She has a personal interest in taking care of patients with Myeloproliferative Neoplasms including Chronic Myeloid Leukemia. Her passion lies in understanding the needs of every patient and always prioritizing and advocating for her patients and their families. Her patient care philosophy involves offering in-depth explanation regarding diagnoses and to engage in active partnership with her patients and their referring providers to personalize decision-making and monitoring given the nature of the

Health-related quality of life and symptom profile of patients with BCR::ABL1-negative myeloproliferative neoplasms: Real-world evidence from the GIMEMA-PROPHECY observational study

Original Publication Date
Article Source
External Web Content

Abstract Health-related quality of life (HRQoL) of patients with myeloproliferative neoplasms (MPNs) may be impaired across several domains. In this multicenter observational study, we evaluated HRQoL and symptoms in a cohort of MPN patients with validated measures, including the…

Rusfertide Continues to Show Strong Results for Polycythemia Vera

Original Publication Date
Article Source
External Web Content

Rusfertide sustained hematocrit control and sharply reduced phlebotomy need through week 52 in PV, showing durable efficacy and a consistent safety profile. Treatment with the hepcidin mimetic rusfertide continued to demonstrate sustained hematocrit control below 45% and high…

Oral Decitabine/Cedazuridine Plus Venetoclax Yields 91% ORR in High-Risk MDS and CMML

Original Publication Date
Article Source
External Web Content

Key Takeaways The combination therapy achieved a 91% overall response rate, with 45% complete remission and 46% marrow complete remission rates. Median overall survival was 30 months, with 1- and 3-year survival rates of 68.8% and 40.7%, respectively. SHOW MORE Decitabine…

Understanding Clinical Trials

Fact Sheet - Understanding Clinical Trials

This guide provides information about clinical trials and gives you some things to consider when deciding whether to take part

Financial Resources

Fact Sheet - Financial Resources

A list of organizations & programs that may provide financial resources & other assistance

Subscribe to Myeloproliferative Neoplasms (MPN)

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.